Holen Sie sich die Stockscreener-App
2.45
2.51%
0.06
Handel nachbörslich:
2.47
0.02
+0.82%
Moleculin Biotech Inc Aktie (MBRX) Neueste Nachrichten
Moleculin Biotech, Inc. Files SEC Form 8-K and Releases May 2026 Investor Presentation - Minichart
Moleculin Biotech (NASDAQ: MBRX) posts new May 2026 investor presentation - Stock Titan
Moleculin Biotech Shares Slide After Announcing 1-for-25 Reverse Split - MSN
Why Did MBRX Stock Plummet Over 25% Today? - MSN
Annamycin cardiac safety data at ASCO 2026 for Moleculin (NASDAQ: MBRX) - Stock Titan
Moleculin presents cardiac safety data for Annamycin at ASCO By Investing.com - Investing.com South Africa
Moleculin's Annamycin shows no heart toxicity in trials, advancing AML cancer treatment. - Pluang
Moleculin presents cardiac safety data for Annamycin at ASCO - Investing.com
Pooled trials of cancer drug Annamycin find no cardiotoxicity signal - Stock Titan
Nano-cap Moleculin Biotech approaches key leukemia trial data unblinding - MSN
MBRX Stock Price, Quote & Chart | MOLECULIN BIOTECH INC (NASDAQ:MBRX) - ChartMill
Moleculin Biotech stock (US60855L2034): Maxim Group keeps Buy rating - AD HOC NEWS
Moleculin Biotech 1Q Loss/Shr $3.54 >MBRX - Moomoo
Why did MBRX stock climb 14% today? - MSN
Moleculin Biotech: Runway to Support Planned Operations Into 3Q 2026 >MBRX - Moomoo
What Does GF Score 27/100 Say About Moleculin Biotech (MBRX) Aft - GuruFocus
Moleculin Biotech, Inc. (NASDAQ: MBRX) Reports Q1 2026 Financial Results and Clinical Trial Updates - Minichart
H.C. Wainwright Maintains Moleculin Biotech(MBRX.US) With Buy Rating, Maintains Target Price $22 - Moomoo
Moleculin Biotech Q1 net loss widens as R&D costs rise - TradingView
Moleculin Biotech Reports Promising Early Results in MIRACLE Trial for AML Treatment with 40% Composite Complete Remission Rate - Quiver Quantitative
MBRX: Pivotal AML trial hits key enrollment, 40% remission rate; Q1 net loss $12.8M, cash runway into Q3 - TradingView
Maxim Group Maintains Moleculin Biotech(MBRX.US) With Buy Rating, Maintains Target Price $10 - Moomoo
Moleculin (NASDAQ: MBRX) Q1 2026 loss deepens while MIRACLE AML trial progresses - Stock Titan
Leukemia trial shows 40% remissions; first MIRACLE data unblinding due June 2026 - Stock Titan
Moleculin Reports First Quarter 2026 Financial Results and Provides Clinical Update on Pivotal MIRACLE Trial - GlobeNewswire
Moleculin Biotech Inc reports results for the quarter ended March 31Earnings Summary - TradingView
MBRX: Annamycin advanced in pivotal AML trial; net loss widened, and more funding is needed for operations - TradingView
Moleculin Biotech, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Moleculin Biotech (MBRX) widens Q1 loss and flags funding gap for MIRACLE trial - Stock Titan
Moleculin reports preliminary data from AML trial ahead of unblinding - Investing.com UK
Nano-Cap Moleculin Biotech Approaches Key Leukemia Trial Data Unblinding - Yahoo Finance
Moleculin Biotech (MBRX) Approaches Key Data Release in AML Tria - GuruFocus
Moleculin Biotech, Inc. Files Form 8-K for May 13, 2026 – Company Details, Stock Info, and Regulatory Disclosures - Minichart
Moleculin Biotech Incto unblind Miracle trial data before June 30, 2026SEC filing - marketscreener.com
Moleculin Nears First Unblinding in Pivotal MIRACLE Trial - TipRanks
Moleculin reports preliminary data from AML trial ahead of unblinding By Investing.com - Investing.com South Africa
Moleculin Announces Imminent MIRACLE Trial Unblinding as Blinded Data Continue to Significantly Outperform Historical Benchmarks - The Manila Times
Moleculin Approaching First MIRACLE Trial Unblinding; Preliminary CR ~30% vs 17–18% SOC - TradingView
Moleculin (NASDAQ: MBRX) posts higher blinded AML remission rates vs cytarabine - Stock Titan
Leukemia study nears June data reveal after early 30% remission rate - Stock Titan
Moleculin Biotech (MBRX) Highlights Annamycin's Cardiac Safety P - GuruFocus
Number of shareholders of Moleculin Biotech, Inc. – NASDAQ:MBRX - TradingView
Moleculin Biotech, Inc. Files 8-K Report with SEC – Company and Stock Information as of May 12, 2026 - Minichart
Moleculin highlights favorable cardiac safety data for Annamycin - TipRanks
Moleculin reports cardiac safety data for Annamycin in AML study By Investing.com - Investing.com South Africa
Moleculin reports cardiac safety data for Annamycin in AML study - Investing.com
Moleculin Biotech, Inc. Publishes Positive Cardiac Safety Data for Annamycin in Relapsed/Refractory AML at EHA 2026 Congress - Quiver Quantitative
Independent Cleveland Clinic Review Finds No Clinically Significant Cardiotoxicity with Moleculin's Annamycin in R/R AML Patients Dosed Beyond Conventional Anthracycline Limits - The Manila Times
Independent Cleveland Clinic review finds no significant cardiotoxicity with Moleculin's Annamycin - TradingView
Cardiac data support Moleculin (NASDAQ: MBRX) Annamycin use in R/R AML - Stock Titan
0.98%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):